Arkolith/Insider Trading/IGC/Form 4

Mukunda Ram

CEO, DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Apr 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
4 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)333K—$04.3M
Apr 1, 2026Option exercise(M)323K$0.26$84K4.6M
Apr 1, 2026Option exercise(M)17K—$0877K
Apr 1, 2026Option exercise(M)33K—$0911K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)333K—$00
Apr 1, 2026Option exercise(M)323K—$0677K
Apr 1, 2026Option exercise(M)17K—$00
Apr 1, 2026Option exercise(M)33K—$033K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-26-001285) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for IGC Pharma, Inc.

Build

Ask your agent about IGC insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001185185-26-001285"
Ask your agent
Use Arkolith to summarize insider buying and selling at IGC Pharma, Inc.
over the last 90 days and cite the filings.